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ABSTRACT
We present our experience on treatment of three children with potentially fatal diseases using a unique
protocol for non-myeloablative bone marrow transplantation. The protocol was designed to promote engraft-
ment of bone marrow stromal/mesenchymal cells (SC/MSCs) based on the knowledge from preclinical models
over the last three decades. Accordingly, our protocol is the first to test the use of bone fragments as an ideal
vehicle to transplant such cells residing in the bone core. Because of the paucity of knowledge for optimum
transplantation of SC/MSCs in humans, we used a multifaceted approach and implanted bone fragments both
intraperitoneally and directly into bone on day 0 of BMT. We also infused cultured donor osteoblast-like cells
intravenously post-BMT. We were able to achieve high levels of stroma cell engraftment as defined by
molecular analyses of bone biopsy specimens.
© 2004 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
The adult mammalian bone marrow microenvi-
onment comprises several different elements that to-
ether are responsible for the support of the hemato-
oietic stem cell, [1-3], B-cell ontogeny [4-6], and
one homeostasis [7,8]. It includes various cell types,
ncluding reticular cells, adipocytes, osteoprogenitors,
ndothelial cells and macrophages, which make up the
troma and are now known collectively as mesenchy-
al cells (reviewed in [8,9]). Early stem cells and B
ells in situ or in vitro have been more closely iden-
iﬁed to be in contact with the endosteal surface in
irect proximity to the osteoblasts as an important
ource of chemokines for homing [10,11], growth fac-
ors for early hemopoiesis [3,12-14], and B cell devel-
pment [15,16]. These stromal cells/mesenchymal
ells (SC/MSCs) can be isolated from the adherent
17-21] and, more recently, from the nonadherent
raction of bone marrow [22,23] as well as bone
24,25]. After bone marrow transplantation (BMT), a
B&MTowever, replacement of these stromal elements does
ot appear to occur and is the subject of considerable
ebate. [8, 26-38] Substitution does not take place
espite the fact that the stroma may be abnormal or
amaged in a variety of malignant and human genetic
iseases (eg, lysosomal storage disease, Fanconi’s ane-
ia, Shwachman-Diamond syndrome, osteogenesis-
mperfecta) [30,39-41]. In malignant disease, the mar-
ow may be further damaged by high-dose
hemotherapy [42-46]. The failure to replace the
troma with donor cells after BMT is thought to be
esponsible for poor engraftment [43,47,48], immune
ecovery [4-6,15], and increased bone turnover [49].
nalysis of the adherent fraction of bone marrow cells
fter BMT has revealed that these cells are mostly of
ecipient origin but may be contaminated with small
opulations of donor macrophages and lymphocytes
35,36,47]. Several studies have tried to engraft cul-
ured SC/MSCs in autologous breast cancer patients
nd allogeneic patients with the skeletal dysplasia of
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7ysosomal storage diseases but to no avail [30,50].
reclinical studies by Ikehara and Good have shown
hat stromal cells from bone fragments placed intra-
eritoneally can migrate to the stromal and other
issues, enhance engraftment, and induce tolerance
cross major histocompatibility complex (MHC) bar-
iers [51-53]. The same group could accomplish re-
lacement of the stroma by directly injecting bone
arrow into the bone marrow cavity [54]. It was also
etermined that the osteoblasts could also facilitate
ngraftment and immune recovery if cotransplanted
ith stem cells [55].
It was our aim to replace the stromal elements of
one marrow in patients with potentially fatal diseases
o improve engraftment and facilitate immune recov-
ry and eventually arrest the underlying disease pro-
ess. This postulate was based on our hypothesis that
o replace the stroma, bone fragments represent the
deal vehicle [21] and contain more SC/MSC cells
24,25], but must be placed in an appropriate micro-
nvironment to receive the appropriate signals for
roliferation and differentiation.
Three patients with potentially fatal disease were
ransplanted in this pilot study. The patient is with
nfantile hypophosphatasia presented with failure to
hrive and progressive rickets at age 6 months. The
econd child was a 9-year-old with Hunter syndrome
ith some involvement of the central nervous system
CNS). Transplantation in Hunter syndrome is con-
roversial [56], despite full lymphohematopoietic en-
raftment, the donors derived enzyme is not trans-
orted to the sites of substrate accumulation. The
urpose was to determine whether the engraftment of
one marrow/peripheral blood as well as stromal cells
ould stop the further accumulation of glycosamino-
lycans in tissues and repair the already damaged
issues, an experiment subsequently tried in 2 other
torage diseases [57]. The third patient had an auto-
mmune disease classiﬁed as overlap syndrome with
asculitis, involving the skin, lung, and CNS. She was
efractory to all immunosuppressive therapy and was a
andidate for an allogeneic transplant.
We used a different approach to standard BMT by
able 1. Donor Stromal Cell Engraftment of Patients Transplanted wi
one Marrow Mesenchymal Cells
Patient Information* Stem Cells†
o. Diagnosis Sex Age Donor TNC C
1 IH F 9 months Dad (4/6) 1.4
2 HS M 9 years Sister (6/6) 3.5
3 AD F 12 years Mom (6/6) 5.0
IH, infantile hypophosphatasia; HS, Hunter syndrome; AD, autoimmu
Bone marrow stem cells, donor source and HLA matching in parenthe
cells count  106/kg on day 0; OBLC, infusion of ex vivo expanded
Percent donor chimerism in peripheral blood mononuclear cells (PBMlacing bone fragments intraperitoneally (IP) and di- m
10ectly into bone along with bone marrow given sys-
emically. Cultured osteoblast-like cells (OBLCs)
ere given by the intravenous (IV) route. Biopsy spec-
mens of the bone rather than bone marrow aspirates
ere used to demonstrate evidence of donor stroma
ngraftment to avoid macrophage contamination.
ATIENTS, MATERIALS AND METHODS
reparative Regimens for Transplantation
The BMT protocol and informed consents were
pproved by All Children’s Hospital Institutional Review
oard. Patient 1, with a mismatched related donor (fa-
her), was conditioned with ﬂudarabine (30 mg/M2  5
ays), low-dose busulfan (8 mg/kg), and anti-thymocyte
lobulin (ATG; 30 mg/kg  3 days), and then infused
ystemically with T-cell–depleted (e-rosetted) bone
arrow cells (Table 1). Two patients with HLA-
atched related donors (patients 2 and 3) underwent a
reparatory treatment of ﬂudarabine (30 mg/M2  5
ays), cyclophosphamide (50 mg/kg  2 days), and TBI
200 cGy) before IV infusion of unfractionated bone
arrow cells from fully matched related donors on day
. All patients received posttransplant immunosuppres-
ion for graft-versus-host disease (GVHD) prophylaxis
ith mycophenolate (MMF), 15 mg/kg p.o. bid for 25
ays, and cyclosporine (CSA), 6.25 mg/kg p.o. bid, until
ood evidence of engraftment or graft rejection was
etermined.
arvesting and Placement of Bone Fragments
The protocol included transplantation of donor
one fragments on day 0. Six bone fragments were
btained from each donor using a Jamshidi biopsy
eedle at the time of bone marrow harvest. Four bone
ragments were then transferred into the adjacent op-
rating room in medium 199 (Gibco, Rockville, MD).
wo bone fragments from the donor were then placed
y the surgeon IP under light anesthesia (Dirrivan;
ensia Sicor, Irvine, CA) through an incision near the
mbilicus. The patient was then placed in the prone
osition for the removal and insertion of 2 bone frag-
actionated Bone Marrow Cells, Bone Chips, and Ex Vivo Expanded
Chimerism‡
Bone chip OBLC (day) PBMNC Bone biopsy (day)
Yes Yes (17) 0%  (606)
Yes Yes (13) 13%30% 26–50% (423)
Yes Yes (13) 81%397% 66% (270)
ase with overlap syndrome and lung vasculitis.
C, total numbers of marrow: cells infused 108/kg containing CD34
OBLCs and posttransplant day of infusion in parentheses.
and bone biopsy on posttransplant days in parentheses.th Unfr
D34
0.2
2.7
1.5
ne dise
sis; TN
donorents. After additional local anesthesia, the biopsy
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SC/MSC Replacement After Bone Marrow Transplantation
Beedle was inserted into the patient’s iliac crest, and a
iece of the recipient’s bone was removed with an
xtraction cannula, with the biopsy needle left in place
n the hole. An extraction cannula with the donor
pecimen was then reinserted into the needle cannula,
ollowed by insertion of a cannula to force the donor
one fragment into the defect.
The remaining 2 donor bone core biopsy speci-
ens were expanded ex vivo for OBLCs. In the pa-
ient with hypophosphatasia (patient 1), the bone har-
est and the implantation procedure were delayed for
7 days because of concern over possible iatrogenic
ffects of ATG on osteoblast cells known to be Thy-
. [58] In addition, this patient had soft bones in-
istinguishable from other soft tissues, thus lacking
rm landmarks to allow the placing of donor bone
ragments directly into the iliac crest.
ultures of Osteoblast-Like Cells
OBLCs were grown in culture using DMEM/F12
edium (Celgro; Fisher, Pittsburgh, PA) containing
0% fetal calf serum (Hyclone, Logan, UT) as origi-
ally described by Robey and Termine [59] with some
odiﬁcation introduced in our laboratories [55].
rieﬂy, under sterile conditions, small pieces of bone
ere placed between 2 glass slides and crushed into
mall particles by gentle pressure and then transferred
nto a tube with medium and vortexed several times to
ash out attached marrow cells. Collagenase (1 mg/
L) (Sigma-Aldrich, St. Louis, MO) was added, and
he tubes were incubated for 2 hours at 37°C with
ontinuous shaking. The contents including the bone
ieces were transferred to plastic culture ﬂasks with
dditional medium and incubated for 10 days at 37°C
nd 5% CO2. The adherent cells were then incubated
ith L-ascorbate (ﬁnal concentration 10 mmol) and
-glycerol phosphate (50 g/mL)(Sigma-Aldrich) for
nother 48 hours, harvested by brief trypsinization,
ashed, counted, suspended in medium 199 and in-
used IV into the patients on days 13 or  17 after
he bone marrow infusion. Because osteoblasts lack
eﬁnitive markers, cells were characterized previously
y morphology as well as by staining for alkaline
hosphatase (staining kit 86-R; Sigma-Aldrich) and
alcium deposition with the von Kossa technique (sil-
er-gelatin) [60]. In our hands, the cells were a ho-
ogenous population of mottled basophilic cells with
ccentric nucleoli and a web-like cytoplasm when
tained with Wright–Giemsa. Although we did not
xclude contamination by other mesenchymal cells,
hese cultures did not have a morphology character-
stic of ﬁbroblasts.
nalysis of Engraftment
Engraftment analysis for donor hematopoietic
tem cells (HSCs) was studied in peripheral blood B
B&MTnd bone marrow cells using ﬂuorescence in situ
ybridization (FISH) for X and Y chromosomes
patients 1 and 2, who had sex-mismatched donors)
r polymerase chain reaction (PCR) for short tan-
em repeat (STR) polymorphisms (patient 3). En-
raftment of donor SC/MSC was isolated from
one core biopsy tissue harvested from the posterior
liac crest using PCR for male-speciﬁc sex-deter-
ining region (SRY) sequences (patient 1) or for
inucleotide and trinucleotide STR polymorphisms
patients 2 and 3). For Patients 1 and 2, the SC/
SC chimerism was studied in freshly harvested
one tissue; the bone core fragment was washed to
urge bone marrow and peripheral blood cells,
round using a mortar and pestle, and pelleted by
entle centrifugation. DNA extracted from cells in
he supernatant was used for PCR. For patient 3,
he chimerism was measured using ex vivo expanded
ultured cells from a bone core biopsy specimen.
he bone fragment was washed, ground, and cul-
ured in RPMI medium with 20% fetal calf serum,
% penicillin, 1% streptomycin, 1% fungizone, and
% L-glutamine for 11 days. All nonadherent cells
ere removed during the culture period. Morpho-
ogically, there was an outgrowth of ﬁbroblast-like
dherent cells in the culture ( 99%). No macro-
hages were seen or tested for. The DNA was
xtracted and analyzed for STR polymorphism.
ISH and PCR Analyses
The FISH and PCR analyses were conducted by
he clinical laboratories of All Children’s Hospital
sing standardized methods with commercially avail-
ble probes (Vysis, Inc, Downers Grove, IL). The
rimers for SRY were SRY (XES2): 5=-CTG TAG
GG TCC CGT TGC TGC GGT G-3= and SRY
XES7): 5=-GAC AAT GCA ATC ATA TGC TTC
GC-3=. The primers for STRs were GABRB3: (for-
ard) 5=-CTC TTG TTC CTG TTG CTT TCA
TA CAC-3= and (reverse) 5=-CAC TGTGCT AGT
GA TTC AGC TC-3= [61]; D9S15: (forward) 5=-
AA AGA TTG GGA GTC AAG TA-3= and (re-
erse) 5=-TTC ACT TGA TGG TGG TAA TC-3=
62]; MDPK: (forward) 5=-GCT CGA AGG GTC
TT GTA GC-3= and (reverse) 5=-GTG GAG GAT
GA ACA CGG AC-3= [63]; and IT15: (forward)
=-ATG AAG GCC TTC GAG GCC TCC CTC
AG TCC TTC-3= and (reverse) 5=-GGC GGT
GC GCC TGT TGC TGC TGC TGC TGC-3=
64]. Fragment sizes were run on 4.5% polyacrylamide
els on an ABI 373A automated analyzer (Applied
iosystems, FosterCity, CA) and analyzed using Ge-
escan and Genotyper software packages (Applied
iosystems).
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7ESULTS
The 3 patients tolerated the BMT protocol with-
ut any complications of GVHD or infections. They
ll have shown clinical improvement in their condi-
ions. The engraftment of donor SC/MSC was con-
incing in these 3 patients, even though 2 patients
acked any evidence of peripheral or bone marrow
ngraftment of donor HSC.
atient 1
A 9-month-old with worsening infantile hy-
ophosphatasia (Figure 1) received bone marrow from
er father (4/6 match) on day 0. She had early post-
ransplant cytogenetics by FISH on days 17 and 55,
hich revealed only host (XX) cells [65]. But 3 months
ost-BMT she showed some unexplained improve-
ent in her clinical condition, marked by correction
f her hypercalcemia and bone pain with an increase
n her appetite and weight. Serial x-rays and DEXA
cans of her bones showed gradual but steady im-
rovement of her osteopenia and severe rickets. A
CR analysis of bone biopsy specimen obtained on
ay 606 revealed a band at the expected base pair
arker of 600 for SRY under increased stringency (at
5°C annealing temperature), suggestive of donor SC/
SC engraftment despite negative PCR on periph-
ral blood or bone marrow cells (even at 60°C anneal-
ng temperature) for donor HSC engraftment. Now at
.6 years post-BMT, the patient is maintaining her
eight (5%) and weight (7%) and exhibits almost
ormal mineralization and complete resolution of the
adiolucencies. She still has mild scoliosis and bowing
f the long bones that is slowly correcting with the
elp of braces (Figure 2).
atient 2
A 9-year-old with mucopolysaccharidosis IIB
Hunter syndrome) received bone marrow from his
LA-matched sister. The ﬁrst cytogenetic study of
is peripheral blood revealed 13% donor cells as mea-
ured by FISH, which over 1 year decreased to 2%
igure 1. Patient 1: patient at 6 months showing the extensive
upping and ﬂaring with associated erosive changes in the metaph-
sis of the right femur.nd ﬁnally to 0. This patient was being followed post- s
12MT at the University of Colorado (Dr. Ralph Qui-
ones) and found to have improvement with increased
oint range of motion. He is now able to open his
ngers and toes, which he was unable to do before the
ransplant. In addition, the extent of his hepatospleno-
egaly is diminishing. There has been no further
eterioration in his condition despite a lack of evi-
ence for any circulating iduronate-2-sulfatase en-
yme activity. The STR analysis of his bone core
iopsy specimen, on posttransplant day 423 using
he MDPK and HD-IT15 microsatellite polymor-
hisms revealed a chimeric status in his bone specimen
t 50% and 25% donor markers, respectively, whereas
onor chimerism of peripheral blood cells was nega-
ive for these markers when measured simultaneously.
atient 3
A 12-year-old girl with very severe autoimmune
isease (overlap syndrome/vasculitis) was given cells
rom her HLA-matched (6/6) mother. She had serial
ytogenetics studies that initially revealed 81%–86%
y day 176. On day  270, the ﬁbroblast cultured
rom a bone biopsy specimen revealed 66% donor
ells as demonstrated by the presence of the donor
olymorphism, FA:D9S15 (Figure 3), whereas the
one marrow specimen was found to be 89% donor.
er last peripheral blood analysis on day640 was all
onor cells without any clinical GVHD during the
osttransplant course. She slowly was weaned off her
SA by 9 months and off daily steroids by 24 months.
urrently, at 39 months posttransplant, she is off all
edicines and in clinical remission.
ISCUSSION
Herein we present a modiﬁed protocol of non-
yeloablative BMT unique for achieving engraftment
f SC/MSCs. Our protocol is distinctive by incorpo-
ating implantation of donor bone fragments both IP
nd directly into bone as well as ex vivo expanded
igure 2. Patient 1: right knee posttransplant at 14, 43, and 49
onths showing correction of the rachitic changes with some re-
idual radiolucencies.
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SC/MSC Replacement After Bone Marrow Transplantation
Bonor bone marrow stromal cells. The protocol de-
eloped was an adaptation of preclinical studies over
he last 3 decades [19,21,51-53]. It was clearly shown
n the laboratories of Drs Good and Ikehara, as well as
thers, that implantation of donor bone intraperito-
eally can promote engraftment of donor stromal cells
s well as donor hematopoietic stem cells
51,52,66,68]. The ﬁrst 2 patients without any evi-
ence of peripheral or bone marrow engraftment had
roof of donor stromal cells by PCR on DNA ex-
racted from crushed bone. In patient 3, who is a
table mixed chimera (97% donor), 66% donor cells
ere detected in ﬁbroblasts cultured from a bone
igure 3. Documentation of successful bone marrow engraftment
sing DNA polymorphisms. The presence of transplant recipient
#5085) and donor (#5086) genotypes was monitored by PCR am-
liﬁcation using the dinucleotide repeat polymorphism at the FA
D9S15) locus. Flags indicate ampliﬁcation fragment sizes in base
airs (upper) and peak height (lower). The bone core biopsy spec-
men (#5366) indicated a donor/recipient chimerism, with a low
evel (7%) of recipient marker. Bone core biopsy cells were sepa-
ated into nonadherent cells (#5367) which were entirely donor
ype, and explanted adherent cells (#5379), which was a chimeric
ixture of 40% recipient/ 60% donor marker.iopsy. p
B&MTControversy remains on the ability of unmanipu-
ated bone marrow cells or expanded mesenchymal
ells to replace the stroma after infusion despite an
bnormal or damaged stroma [8,26,28-30,32,34-
8,57,69,70]. One of the ﬁrst reports of the replace-
ent of stroma with host cells after allogeneic BMT
as in 1982 [29]. However, subsequent studies by
thers have not demonstrated engraftment of donor
ells [30,32,35,36,57,71,72]. Simmons et al. were the
rst to look comprehensively at the stroma and found
hat the FISH positive donor derived cells were also
ositive for nonspeciﬁc esterase (NSE), [35] a
arker for macrophages. This may have accounted for
he false-positive results in some of the previous and
urrent studies [28,29,38,57]. Agematsu et al. per-
ormed in situ hybridization studies using Southern-
lot analysis and PCR with MCT 118 probes on
ultured ﬁbroblasts and found all the cells to be of
ecipient origin [32]. Lee et al. were concerned over
he high incidence of bone turnover, or osteoporosis
fter transplant [49]. They isolated and induced bone
arrow cells to osteoblastic lineage in 7 patients and
ompared them to cultured cells from their donors.
o recipient had evidence of donor osteoblasts as
etermined by PCR analysis using YN222 mini-satel-
ite probes. Koc et al. analyzed 13 patients with lyso-
omal and peroxisomal storage disease 1–14 years after
MT and found no evidence of donor cells in the
tromal compartment despite having skeletal dysplasia
nd damaged nervous tissue [30]. Subsequently, they
ried to correct both defects by giving expanded
5,000-–10,000-fold) mesenchymal cells at doses of
pproximately 2–10  106/kg, plus bone marrow in a
rospective study [57]. In 2 of the 11 patients, they
ound less than 2% donor cells. There was no im-
rovement of their skeletal dysplasia despite evidence
hat the expanded cells retained the capacity to form
steoprogenitors. However, this technique may have
nhanced engraftment and prevented serious GvHD
30,57,70].
In Seattle 15 years later Awaya et al. continued
heir earlier studies from 1987 to see if patients 1–27
ears post-BMT had now replaced the stroma after
ull engraftment. Again, they found only small num-
ers of donor cells, 8.5% (range, 0–8.5%), from 3
atients in long-term bone marrow cultures that were
SE [36]. Using a different technique in one patient
years after conventional BMT, Awaya et al. estab-
ished long-term cultures from a bone biopsy speci-
en [36]. Despite 100% donor engraftment in the
one marrow, there were less than 0.5% donor cells,
nd 0.1% were NSE cells detected in the culture.
arlier reports by other investigators had demon-
trated 2.0% donor cells in the stroma isolated from
one marrow after BMT [28,29,38,57].
We tried to circumvent the problem of macro-hage contamination by analyzing only bone biopsy
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7pecimens for donor SC/MSC engraftment. Of the
rst 2 patients, neither had evidence of HSC engraft-
ent in the peripheral blood or bone marrow but
atient 2 had 25% donor cells in his bone biopsy
pecimen. Patient 3=s bone biopsy specimen at day 
70 was cultured for 11 days and grew only ﬁbroblast
 99%). No macrophages were seen. The ﬁbroblasts
ere at least 60% donor, as determined by 2 separate
onor probes.
There has been no good explanation for the lack
f stromal and nonhematopoietic tissue engraftment
fter the systemic infusion of bone marrow or mesen-
hymal cells. This question was studied by Noort et
l., who examined the homing of fetal mesenchymal
ells (fMSCs) as well as the effect on engraftment of
tem cells derived from human cord blood in an ani-
al model [73]. The expanded fMSCs from fetal lung
howed a ﬁbroblast-like morphology and were able to
ifferentiate into osteoblasts or adipocytes. Although
otransplantation of the fMSCs enhanced engraft-
ent of the human cord blood, these investigators
ound the fMSCs exclusively in the lung. They hy-
othesized that the fMSCs were trapped permanently
n the lung and were thus unable to migrate to other
issues. This hypothesis was disproven by the intra-
ardiac injection of the fMSCs, which failed to show
ny cells in the lung as well as other tissues. The cells
xpanded in culture lost their expression of CD34 as
ell as of CD50, CD102, CD106, and L-selectin.
ther groups also found the loss of adhesion mole-
ules after culture [15,74,75], including the functional
xpression of all CCR- and CXCR-family members
ith failure to migrate across Transwell ﬁlters [76-
8]. These studies suggest that the loss of these adhe-
ion molecules is responsible for the lack of homing
nd engraftment. Banﬁ et al. found that MSCs even
fter the ﬁrst passages lost some of their ability to
roliferate and to differentiate into multiple cell types
79]. The osteogenic potential of these expanded cells
lso decreased when compared with fresh ﬁbroblasts
solated from bone marrow. Devine et al in a prelim-
nary study in a nonprimate model after systemic in-
usion demonstrated early homing but nonsustainable
ngraftment of gene marked mesenchymal cells in
ecipients’ bone and bone marrow [69]. Subsequently,
n a follow-up study they were able to show that a very
mall number (0.1%–2.7%) of cells homed only to and
ersisted in nonhematopoietic tissues [80].
Although infusion of the ex vivo expanded cells
ay prove useful, the vehicle providing 3-dimensional
caffolding for the SC is likely to be crucial for intro-
ucing large numbers of SCs with preserved func-
ional and morphological properties [21,25,67,68,81-
3]. Krebsbach repeated and expanded the earlier
xperiments of Friedenstein and Haynesworth [84] by
omparing CFU-F derived from mice and humans
21]. New bone formation was observed in the human
14ells only if they were absorbed onto hydroxyapatite/
eramics or ﬁrst subjected to osteoinductive media
efore being placed in diffusion chambers. They con-
luded that the vehicle was important for the proper
roliferation and differentiation of these cells into
one.
Reports of the cotransplantation of cultured MSCs
nd HSC may have enhanced engraftment [50,57,85].
ur method did not enhance engraftment of HSC after
nonmyeloablative preparative regimen in 2 of the 3
atients. This problem is commonly seen in nonmalig-
ant diseases, where the immune system is relatively
ntact. The exception was patient 3, who had long-term
mmunosuppressive therapy for her autoimmune disease
efore the transplant. Also, the infusion of OBLCs was
hought to be insigniﬁcant due to the small numbers of
ells (ratio of 1 to 15,000 TNC) and the data from others
howing that these expanded/cultured cells do not en-
raft when given systemically [21,57,73]. However, we
annot rule out an initial effect on HSC engraftment
hen the OBLCs are cotransplanted [55,69,86] or with
one fragments [51] that can be sustained only in pa-
ients with adequate immunosuppression. The impor-
ance of replacing the host SC/MSCs with this method
ay be more advantageous for treating bone diseases
ike hypophosphatasia, osteogenesis imperfecta, and the
keletal dysplasia of lysosomal disease. In bone diseases,
roviding even a small amount of normal SC/MSCsmay
e all that is needed for the osteoprogenitor cells to
ndergo self-renewal, proliferation, and differentiation
fter receiving the appropriate signals from the modiﬁed
ost microenvironment.
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